This article is more than 5 years old. Information may no longer be current.
Novaliq announces positive phase 1 results for dry eye drops
Novaliq has announced positive phase 1 results for its dry eye agent, CyclASol, according to a press release.
Eighteen healthy patients were included in the phase 1, double-blind, randomized, placebo-controlled crossover study that investigated the safety, local tolerability and systemic exposure of CyclASol (0.05% cyclosporin solution, Novaliq) eye drops and vehicle after single and multiple ocular doses.
“For patients with dry eye disease, there are few approved drug options available,” Dieter Scherer, PhD, Novaliq’s chief scientific officer, said in the press release. “Cyclosporin is a well-accepted active drug substance for this disease, although current formulations come with several limitations, including side effects and limited patient acceptance due to cyclosporin’s poor solubility.”
No adverse events related to the drug were reported, and no systemic levels of cyclosporin were detected after any dose, according to the release.